Coherus BioSciences (NASDAQ:CHRS) shareholder returns have been notable, earning 72% in 3 years

Low-cost index funds make it easy to achieve average market returns. But in any diversified portfolio of stocks, you'll see some that fall short of the average. Unfortunately for shareholders, while the Coherus BioSciences, Inc. (NASDAQ:CHRS) share price is up 72% in the last three years, that falls short of the market return. Zooming in, the stock is up just 3.5% in the last year.

The past week has proven to be lucrative for Coherus BioSciences investors, so let's see if fundamentals drove the company's three-year performance.

Check out our latest analysis for Coherus BioSciences

Because Coherus BioSciences made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. When a company doesn't make profits, we'd generally expect to see good revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

Coherus BioSciences' revenue trended up 56% each year over three years. That's much better than most loss-making companies. While long-term shareholders have made money, the 20% per year gain over three years isn't that great given the rising market. We would have thought the top-line growth might have impressed buyers more. If the business can trend towards profitability and fund its growth, then the market could present an opportunity. But you might want to take a closer look at this one.

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).

Take a more thorough look at Coherus BioSciences' financial health with this free report on its balance sheet.

A Different Perspective

Coherus BioSciences provided a TSR of 3.5% over the last twelve months. But that return falls short of the market. On the bright side, that's still a gain, and it is certainly better than the yearly loss of about 6% endured over half a decade. So this might be a sign the business has turned its fortunes around. It's always interesting to track share price performance over the longer term. But to understand Coherus BioSciences better, we need to consider many other factors. For example, we've discovered 3 warning signs for Coherus BioSciences that you should be aware of before investing here.

Of course Coherus BioSciences may not be the best stock to buy. So you may wish to see this free collection of growth stocks.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.